Pro Medicus Ltd
ASX:PME
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
87.24
268.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Pro Medicus Ltd
Pro Medicus Ltd
Total Liabilities & Equity
Pro Medicus Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pro Medicus Ltd
ASX:PME
|
Total Liabilities & Equity
AU$257.4m
|
CAGR 3-Years
27%
|
CAGR 5-Years
25%
|
CAGR 10-Years
24%
|
|
|
4DMedical Ltd
ASX:4DX
|
Total Liabilities & Equity
AU$120m
|
CAGR 3-Years
9%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
CogState Ltd
ASX:CGS
|
Total Liabilities & Equity
$57.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
25%
|
CAGR 10-Years
15%
|
|
|
Medibio Ltd
ASX:MEB
|
Total Liabilities & Equity
AU$8.1m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Medadvisor Ltd
ASX:MDR
|
Total Liabilities & Equity
AU$98.8m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
64%
|
|
|
Alcidion Group Ltd
ASX:ALC
|
Total Liabilities & Equity
AU$114.5m
|
CAGR 3-Years
25%
|
CAGR 5-Years
36%
|
CAGR 10-Years
40%
|
|
Pro Medicus Ltd
Glance View
Pro Medicus Ltd, an Australian company founded in 1983, has etched its name in the field of healthcare IT, primarily through its innovative medical imaging software solutions. The brainchild of Dr. Sam Hupert and Anthony Hall, the company originally sought to provide radiology practices with digital solutions for image management and viewing. Over the years, Pro Medicus has meticulously evolved its offerings to become a leader in picture archiving and communication systems (PACS), radiology information systems (RIS), and an expanding range of e-health solutions. Its flagship product, Visage 7, is renowned for delivering fast and sophisticated viewing capabilities, enabling radiologists to efficiently interpret complex imaging data. Under its hood, the company’s technology is powered by advanced streaming capabilities, allowing for large files to be quickly accessed and reviewed, essential for high-demand environments. The monetization model of Pro Medicus largely revolves around licensing agreements for its software, alongside service and support fees, ensuring a steady and recurring revenue stream. The company has successfully leveraged its expertise to penetrate key markets, notably the United States and Europe, where it partners with some of the most prestigious hospitals and research institutions. By focusing on high-end offerings and fostering long-term client relationships, Pro Medicus has cemented a premium positioning in the healthcare IT landscape. The strategic focus on innovation, coupled with a keen understanding of the evolving needs of healthcare providers, allows Pro Medicus to continually refine its services, ensuring it remains at the forefront of technological advancements that ultimately enhance diagnostic efficiency and patient outcomes.
See Also
What is Pro Medicus Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
257.4m
AUD
Based on the financial report for Jun 30, 2024, Pro Medicus Ltd's Total Liabilities & Equity amounts to 257.4m AUD.
What is Pro Medicus Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
24%
Over the last year, the Total Liabilities & Equity growth was 27%. The average annual Total Liabilities & Equity growth rates for Pro Medicus Ltd have been 27% over the past three years , 25% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet
